evaluate the safety of unmanipulated HSCT from a 2-or 3-locus-mismatched family donor using alemtuzumab only in vivo and have shown that alemtuzumab is very effective for preventing GVHD. 7 However, eight of the 14 patients developed grade II-III cardiac complications according to Bearman's criteria. 8 We describe the clinical course of cardiac complications after HLA-mismatched HSCT using in vivo alemtuzumab. In addition, we report the results of retrospective analyses that evaluated whether the use of in vivo alemtuzumab was an independent risk factor for cardiac complications after adult allogeneic HSCT.
Patients and methods

Transplantation procedure
The study to evaluate the safety of unmanipulated HSCT from 2-or 3-locus-mismatched family donors using in vivo alemtuzumab was started in March 2002 after approval by the ethics committee of the University of Tokyo Hospital. The transplantation procedure has been described in detail elsewhere. 7 Briefly, the conditioning regimen consisted of total body irradiation (TBI) at 2 Gy twice daily for 3 days and cyclophosphamide at 60 mg/kg/day for 2 days. The dose of cyclophosphamide was decreased to 20 mg/kg/day for 2 days, and etoposide at 40 mg/kg/day was added instead in a patient with impaired cardiac function due to anthracyclines. For elderly patients, a non-TBI containing regimen consisting of fludarabine at 30 mg/kg/day for 6 days and busulfan at 1 mg/kg four times daily for 4 days was used. After November 2003, we added TBI at 2 Gy twice daily on day À1 and decreased the dose of busulfan to 4 mg/kg/day for 2 days. Alemtuzumab was added to these regimens at 0.2 mg/kg/day for 6 days (days À8 to À3), following pretreatment with 1 mg/kg of methyl-prednisolone. Cryopreserved donor peripheral blood (PB) stem cells were infused on day 0 without ex vivo manipulation. GVHD prophylaxis was with cyclosporine A and shortterm methotrexate. Cyclosporine was started on day À1 at a dose of 3 mg/kg/day by continuous infusion and the dose was adjusted to maintain a blood concentration between 250 and 350 ng/ml. Cyclosporine was changed to an oral form when it could be tolerated by the patient. Methotrexate was administered at 15 mg/m 2 on day 1, and 10 mg/m 2 on days 3, 6, and 11. For patients without acute GVHD, we started to taper cyclosporine from day 30 by 10% per week and discontinued it on day 100.
Analyses of risk factors for cardiac complications
After we observed grade II-IV cardiac complications according to Bearman's criteria in eight of the 14 patients who underwent HLA-mismatched HSCT using in vivo alemtuzumab, we retrospectively analyzed the records of all adult patients who had undergone allogeneic HSCT for the first time between June 1995 and June 2004 at the University of Tokyo Hospital. In the following statistical analyses, we included 142 patients for whom standard 12-lead electrocardiogram (ECG) and ultrasound cardiography (UCG) within 3 months before transplantation were available. We routinely performed these procedures on all patients before conditioning. Among them, 14 patients underwent 2-or 3-locus-mismatched HSCT using in vivo alemtuzumab, whereas the remaining 128 patients underwent HLA-matched or 1-locus-mismatched HSCT using standard GVHD prophylaxis with cyclosporine or tacrolimus combined with methotrexate. Cyclophosphamide at more than 100 mg/kg was used in 107 patients and TBI was used in 95 patients. The stem cell source was bone marrow (BM) in 94 patients and PB stem cells in 48. Cardiac complications observed within 28 days after HSCT were considered regimen-related toxicities and grouped according to Bearman's criteria. 8 Potential confounding factors considered in the statistical analyses were age, sex, status of underlying disease, previous cardiac disease, smoking, serum ferritin level, cumulative dose of anthracyclines, irradiation involving the heart, heart rate, blood pressure, QT interval, QT dispersion, left ventricular ejection fraction (LVEF) evaluated by UCG, dose of cyclophosphamide in the conditioning regimen, use of TBI, use of alemtuzumab, stem cell source (BM or PB), serological/genotypical HLA-mismatch, and donor type (related or unrelated). Details of the methods used to measure these parameters have been described previously. 9 For univariate analyses, continuous variables in the two groups were compared using the unpaired t-test or the Mann-Whitney U-test, whereas categorical variables were compared using the Fisher's exact test. Factors associated with at least borderline significance (Po0.10) on univariate analysis were subjected to multivariate analysis using logistic regression. P-values of less than 0.05 were considered statistically significant.
Results
HLA-mismatched HSCT using in vivo alemtuzumab
In total, 14 patients underwent 2-or 3-locus-mismatched HSCT using in vivo alemtuzumab. There were eight males and six females with a median age of 49.5 years (range 27-60). Nine patients had active disease at transplantation. Eight received a TBI-based regimen, while six received a fludarabine-based regimen. The median number of CD34 þ and CD3 þ cells in the graft was 5.1 Â 10 6 cells/kg (range 4.3-7.7) and 2.5 Â 10 8 cells/kg (range 1.0-7.1), respectively. All patients achieved donor cell engraftment and complete donor-type chimerism with a median duration to neutrophil recovery 4500/mm 3 of 18.5 days and platelet recovery 420 000/mm 3 of 18.0 days. Only two patients developed grade II-IV acute GVHD; one patient each with grade II and III, respectively. Infection-related death was observed in one patient who died of cytomegalovirus pneumonitis on day 98. Grade II-IV regimen-related toxicities according to Bearman's criteria were observed as follows: stomatitis in nine patients, renal toxicity in two, liver toxicity in one, and cardiac toxicity in eight (57.1%), mainly with congestive heart failure ( Table 1) . Six patients developed grade II cardiac toxicity diagnosed by an increased cardiothoracic ratio, which was detected by routine X-ray and required the use of diuretics. Grade III cardiac toxicities were observed in two patients who responded poorly to diuretics and required catecholamines. One of them showed markedly decreased left ventricular function (EF of 24%) on UCG. Another patient had paroxysmal supraventricular tachycardia. Treatment with catecholamines resolved the symptoms in both patients. There were no long-term sequelae except that one patient with grade III cardiac toxicity showed persistent LV dysfunction on UCG.
Retrospective analyses to identify risk factors for cardiac complications
Of the 142 patients included in the retrospective analysis, 23 (16.2%) and 10 (7.0%) patients developed grade II-IV and III-IV cardiac complications, respectively, within 28 days after transplantation. The median onset of cardiac complication was 13.5 and 4.5 days after HSCT in patients who received alemtuzumab and those who did not, respectively (P ¼ 0.02; Figure 1 ). Seven died of cardiac causes a median of 3 days after the onset of cardiac complications, but all the cardiac complications in the alemtuzumab group were successfully treated with diuretics and/or catecholamines.
Univariate analyses to evaluate the impact of possible confounding factors on the incidence of grade II-IV cardiac complications identified eight factors with a P-value less than 0.10: smoking history (P ¼ 0.036), serum ferritin level (P ¼ 0.033), cumulative dose of anthracyclines (P ¼ 0.001), heart rate (P ¼ 0.084), EF (P ¼ 0.070), serological HLA-mismatch (P ¼ 0.054), genetic HLA-mismatch (P ¼ 0.087), and the use of alemtuzumab (P ¼ 0.0002) (Table 2a) .
Among these, only the cumulative dose of anthracyclines (odds ratio 1.003, 95% confidence interval (CI) 1.001-1.005, P ¼ 0.0016) and the use of alemtuzumab (OR 12.1, 95% CI 3.3-44.1, P ¼ 0.001) were identified as independent significant risk factors on multivariate analysis (Table 2b) .
Discussion
Generally, cardiac complications are uncommon after treatment with alemtuzumab. [10] [11] [12] [13] However, a high incidence of cardiac complications was reported in four of Cardiac complications after HLA-mismatched HSCT using alemtuzumab K Oshima et al eight patients who received alemtuzumab for mycosis fungoides or Se´zary syndrome. 14 The expression of CD52 was not observed on cardiac myocytes and, thus, cytokine-release syndrome after alemtuzumab infusion was considered to be responsible for the cardiac complications, 14 because inflammatory cytokines such as tumor necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6) have been reported to be responsible for the development and progression of heart failure. 15, 16 The frequent cardiac complications in our HLA-mismatched HSCT study could not be explained solely by alemtuzumab, since cardiac complications were infrequently mentioned in HLA-matched HSCT with reducedintensity conditioning. [2] [3] [4] [5] [6] Therefore, cardiac complications in our series might have resulted not only from alemtuzumab but also from the intensive conditioning and/or increased cytokine secretion associated with the engraftment of HLA-mismatched donor cells. In fact, the median duration to cardiac complications after HSCT was significantly longer in patients who received alemtuzumab and most of the cardiac complications after allogeneic HSCT using alemtuzumab were observed in the periengraftment period (Table 1) , when the secretion of various cytokines is known to increase. 17 We monitored cardiac function after HSCT by daily measurements of body weight, pulse oximeter oxygen saturation and weekly chest X-ray. Thus, we were able largely to avoid fatal cardiac complications after HSCT using alemtuzumab. However, two patients developed grade III cardiac complications that required catecholamine support. An evaluation of the value of possibly more sensitive markers, such as plasma brain natriuretic peptide level, is thus warranted. 18 The use of diuretics may be sufficient if cardiac complications can be detected at an early stage.
In conclusion, although in vivo alemtuzumab is very effective for preventing GVHD even in HLA-mismatched HSCT, the use of in vivo alemtuzumab along with myeloablative conditioning for HLA-mismatched HSCT may increase the incidence of reversible cardiac compli- 
